Who is sponsoring NCT00312481?

NCT00312481 is sponsored by Norgine.

What condition does NCT00312481 study?

NCT00312481 studies Colonoscopy.

What drugs are being tested in NCT00312481?

Interventions: macrogol3350 NA sulphate NACL KCL ascorbic acid NA ascorbate, NA picosulfate magnesium citrate.

What is the status of NCT00312481?

NCT00312481 is currently COMPLETED.

Last reviewed 2007-12-12 · How we verify

A Randomised, Single-Centre, Parallel-Group, Pilot Study to Assess the Efficacy, Safety and Patient Acceptability of a New 2-Litre Bowel Preparation Agent (MOVIPREP®) Compared With a Standard Bowel Preparation Agent (PICOLAX®)

NCT00312481 Phase 2 COMPLETED

This will be a randomised, single-centre, single-blind, parallel-group, pilot study in patients undergoing colonoscopy. The primary objective is to evaluate the efficacy of MOVIPREP® versus PICOLAX® for gut cleansing prior to colonoscopy. The secondary objectives are to evaluate the safety, tolerability and acceptability of MOVIPREP versus PICOLAX for gut cleansing prior to colonoscopy.

Details

Lead sponsor	Norgine
Phase	Phase 2
Status	COMPLETED
Enrolment	65
Start date	2005-07
Completion	2006-05

Conditions

Colonoscopy

Interventions

macrogol3350 NA sulphate NACL KCL ascorbic acid NA ascorbate
NA picosulfate magnesium citrate

Primary outcomes

Overall quality of the bowel preparation treatment, based on the degree of gut cleansing of each section of the colon. — 8 days

Countries

United Kingdom